دورية أكاديمية
Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations.
| العنوان: | Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations. |
|---|---|
| المؤلفون: | Cocciolone V; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.; Medical Oncology Department, S. Salvatore Hospital, University of L'Aquila, L'Aquila, Italy., Cannita K; Medical Oncology Department, S. Salvatore Hospital, University of L'Aquila, L'Aquila, Italy., Tessitore A; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy., Mastroiaco V; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy., Rinaldi L; Medical Oncology Department, S. Salvatore Hospital, University of L'Aquila, L'Aquila, Italy., Paradisi S; Medical Oncology Department, S. Salvatore Hospital, University of L'Aquila, L'Aquila, Italy., Irelli A; Medical Oncology Department, S. Salvatore Hospital, University of L'Aquila, L'Aquila, Italy., Baldi PL; Medical Oncology Department, S. Salvatore Hospital, University of L'Aquila, L'Aquila, Italy., Sidoni T; Medical Oncology Department, S. Salvatore Hospital, University of L'Aquila, L'Aquila, Italy., Ricevuto E; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.; Oncology Network ASL1 Abruzzo, UOSD Oncology Territorial Care, S. Salvatore Hospital, University of L'Aquila, L'Aquila, Italy., Dal Mas A; Pathology Department, S. Salvatore Hospital, L'Aquila, L'Aquila, Italy., Calvisi G; Pathology Department, S. Salvatore Hospital, L'Aquila, L'Aquila, Italy., Coletti G; Pathology Department, S. Salvatore Hospital, L'Aquila, L'Aquila, Italy., Ciccozzi A; Radiology Department, S. Salvatore Hospital, L'Aquila, L'Aquila, Italy., Pizzorno L; Breast Unit, S. Salvatore Hospital, L'Aquila, L'Aquila, Italy., Resta V; Breast Unit, S. Salvatore Hospital, L'Aquila, L'Aquila, Italy., Bafile A; Breast Unit, S. Salvatore Hospital, L'Aquila, L'Aquila, Italy., Alesse E; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy., Ficorella C; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.; Medical Oncology Department, S. Salvatore Hospital, University of L'Aquila, L'Aquila, Italy. |
| المصدر: | Oncotarget [Oncotarget] 2018 Jun 08; Vol. 9 (44), pp. 27380-27396. Date of Electronic Publication: 2018 Jun 08 (Print Publication: 2018). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: eCollection Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Albany, N.Y. : Impact Journals |
| مستخلص: | Background: Dose-dense chemotherapy is one of the treatments of choice for neoadjuvant therapy in breast cancer (BC). Activating mutations in PIK3CA gene predict worse response to neoadjuvant chemotherapy for HER2-positive patients, while their role is less clearly defined for HER2-negative tumors. Methods: We conducted a phase I/II study of neoadjuvant, sequential, dose-dense anthracycline/taxane chemotherapy, plus trastuzumab in HER2-positive patients and investigated the correlation of pre-treatment PIK3CA mutation status with pathologic complete response (pCR) and long-term outcome in a real-life setting. Results: we established a dose-dense docetaxel recommended dose of 60 mg/m 2 and 65 mg/m 2 , with or without trastuzumab, respectively, according to HER2-status, following dose-dense epirubicin-cyclophosphamide (90/600 mg/m 2 ), every 2 weeks. The overall pCR rate was 21.4%; median disease-free survival (DFS) was 52 months and median overall survival (OS) was not yet reached. PIK3CA mutation status was not significantly associated with the pCR rate: 18% for both mutated and wild-type patients. The pCR rate was: 25% in the mutated and 24% in the wild-type (p 0.560) cohort of the HER2-positive subgroup; 33% both in the mutant and wild-type cohort of the triple-negative subgroup; no pCR neither in the mutant nor in the wild-type cohort of the HR-positive/HER2-negative subgroup. Among the HER2-positive population, a trend toward worse DFS was observed in case of mutation, as opposed to the triple negative population. Conclusions: This study proposes an effective and safe neoadjuvant dose-dense anthracycline/taxane schedule and suggests that PIK3CA mutation analysis can be usefully performed in real-life clinical practice. Competing Interests: CONFLICTS OF INTEREST The authors declare that they have no competing interests. |
| References: | Clin Transl Oncol. 2011 Sep;13(9):686-91. (PMID: 21865141) J Natl Cancer Inst. 2005 Feb 2;97(3):188-94. (PMID: 15687361) PLoS One. 2014 Dec 26;9(12 ):e116054. (PMID: 25542038) Breast Cancer Res Treat. 2010 Jul;122(2):429-37. (PMID: 20480225) J Clin Invest. 2011 Jul;121(7):2750-67. (PMID: 21633166) J Clin Oncol. 2005 Apr 20;23(12):2676-85. (PMID: 15837982) Oncologist. 2015 Feb;20(2):109-10. (PMID: 25601964) Lancet. 2010 Jan 30;375(9712):377-84. (PMID: 20113825) J Clin Oncol. 2015 Apr 20;33(12):1334-9. (PMID: 25559818) J Clin Oncol. 2007 Oct 1;25(28):4414-22. (PMID: 17785706) Breast Cancer Res. 2014 Aug 08;16(4):406. (PMID: 25103565) Cancer Chemother Pharmacol. 2005 Oct;56(4):361-9. (PMID: 15868146) Breast. 2011 Dec;20(6):485-90. (PMID: 21784637) Cancer Sci. 2015 Nov;106(11):1582-9. (PMID: 26353837) Oncotarget. 2014 Oct 30;5(20):9952-65. (PMID: 25296970) Lancet Oncol. 2012 Jan;13(1):25-32. (PMID: 22153890) Clin Cancer Res. 2007 Apr 15;13(8):2329-34. (PMID: 17438091) Biomed Res Int. 2014;2014:628217. (PMID: 24783217) J Clin Oncol. 2009 Jun 1;27(16):2630-7. (PMID: 19380449) Ann Oncol. 2007 Jun;18(6):1015-20. (PMID: 17369601) Biometrics. 1989 Sep;45(3):925-37. (PMID: 2790129) J Natl Cancer Inst. 2010 Dec 15;102(24):1845-54. (PMID: 21098761) Breast Cancer Res. 2008;10(2):R27. (PMID: 18371219) Ann Oncol. 2013 Dec;24(12 ):2978-84. (PMID: 24136883) Ann Oncol. 2014 Jun;25(6):1122-7. (PMID: 24669015) Cancer Res. 2008 Aug 1;68(15):6084-91. (PMID: 18676830) Lancet. 2014 Jul 12;384(9938):164-72. (PMID: 24529560) J Clin Oncol. 2001 Nov 15;19(22):4224-37. (PMID: 11709566) Lancet Oncol. 2012 Jun;13(6):e240-8. (PMID: 22652232) J Clin Oncol. 2005 Jun 1;23(16):3676-85. (PMID: 15738535) Ann Oncol. 2013 Sep;24(9):2278-84. (PMID: 23704196) Clin Cancer Res. 2016 Jun 1;22(11):2675-83. (PMID: 26758558) Breast Cancer Res Treat. 2006 Jun;97(3):311-8. (PMID: 16344915) J Clin Oncol. 2003 Nov 15;21(22):4165-74. (PMID: 14559892) J Clin Oncol. 1999 Oct;17(10):3033-7. (PMID: 10506597) Lancet Oncol. 2013 Dec;14(13):1317-25. (PMID: 24239210) Lancet Oncol. 2014 May;15(6):640-7. (PMID: 24657003) Semin Oncol. 1997 Aug;24(4 Suppl 10):S10-3-S10-10. (PMID: 9275000) Oncologist. 2015 Sep;20(9):1001-10. (PMID: 26245675) J Natl Cancer Inst. 2013 Jul 3;105(13):960-7. (PMID: 23739063) Curr Oncol. 2013 Jun;20(3):e180-92. (PMID: 23737688) Eur J Cancer. 1995 Nov;31A(12):1969-75. (PMID: 8562150) J Natl Cancer Inst. 2005 Dec 7;97(23):1712-4. (PMID: 16333021) Lancet. 2012 Feb 18;379(9816):633-40. (PMID: 22257673) J Clin Oncol. 1999 Feb;17(2):460-9. (PMID: 10080586) Ann Oncol. 2016 Aug;27(8):1519-25. (PMID: 27177864) J Clin Oncol. 2011 Sep 1;29(25):3351-7. (PMID: 21788566) Nature. 2012 Oct 4;490(7418):61-70. (PMID: 23000897) J Clin Oncol. 2014 Oct 10;32(29):3212-20. (PMID: 25199759) Eur J Cancer. 2010 Aug;46(12):2216-24. (PMID: 20471822) J Clin Oncol. 2003 Apr 15;21(8):1431-9. (PMID: 12668651) J Clin Oncol. 2012 Jun 1;30(16):1989-95. (PMID: 22493419) J Clin Oncol. 2014 Nov 20;32(33):3753-61. (PMID: 25332247) Ann Oncol. 2008 May;19(5):861-70. (PMID: 18174609) Lancet Oncol. 2013 Nov;14(12):1183-92. (PMID: 24095300) Eur J Cancer. 2012 Dec;48(18):3342-54. (PMID: 22766518) |
| فهرسة مساهمة: | Keywords: PIK3CA; dose-dense; neaodjuvant; real life |
| تواريخ الأحداث: | Date Created: 20180626 Latest Revision: 20220321 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC6007957 |
| DOI: | 10.18632/oncotarget.25270 |
| PMID: | 29937992 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1949-2553 |
|---|---|
| DOI: | 10.18632/oncotarget.25270 |